Venetoclax shows promise for r/r hairy cell leukemia
Italian study suggests benefits of administering venetoclax for patients with r/r cases of hairy cell leukemia, a rare blood cancer,
Transplant vs. chemo: Similar AML survival rates
New study showed similar survival rates among AML patients treated solely with consolidation chemotherapy and those who received allogenic HCT.
Drug combo holds promise of better AML outcomes
Study suggests that the venetoclax-gilteritinib drug combination “potentially improves response frequency and depth.”
Pivotal trials in blood cancers don’t mirror patient populations
“The results from this study should lead to questions about the generalizability of drug safety and efficacy in populations we serve as medical...
AML’s seasonal peak suggests viral or environmental etiology
“The environmental triggers involved could be radiation, pollution, allergens, or infectious agents like viruses.”
Evidence still lacking that vitamins prevent CVD, cancer: USPSTF
In its final recommendation statement on the subject, the task force does, however, recommend against use of vitamin E and beta-carotene.
‘Extremely exciting’ study results guide MM treatment options
New trial data help inform the tailoring of effective treatment approaches for patients with newly diagnosed multiple myeloma (MM).
Clozapine and cancer risk in schizophrenia patients: New data
The clozapine-related risk increase was specific to hematological malignancies only.
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.